{"title":"CCN2: a potential contributor to gingival overgrowth.","authors":"Asmaa Fadl, Andrew Leask","doi":"10.1016/j.job.2024.100587","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Fibrotic responses in the gingiva are characterized by their hyperproliferative nature instead of scar tissue formation. Clinically, these conditions appear as \"gingival overgrowth\" (GO), which can be of drug-induced or genetic origin. Despite surgical removal, GO can recur. Therefore, non-invasive methods of treating GO are required. In other fibrotic systems, the matricellular protein CCN2 represents a potential therapeutic target. However, CCN2 has been relatively understudied in the context of GO.</p><p><strong>Highlight: </strong>Herein, we describe what is known regarding CCN2 expression in GO and gingival fibroblasts. Specifically, CCN2 is induced by agents that promote fibrogenesis in the oral cavity, such as transforming growth factor-β, and drugs that promote GO, such as cyclosporine, nifedipine, and phenytoin.</p><p><strong>Conclusion: </strong>Although little is known regarding the possible function of CCN2 in GO, given the correlation between CCN2 expression and GO recurrence, we hope that this review will inspire further research on this topic.</p>","PeriodicalId":45851,"journal":{"name":"Journal of Oral Biosciences","volume":" ","pages":"100587"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Oral Biosciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.job.2024.100587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Fibrotic responses in the gingiva are characterized by their hyperproliferative nature instead of scar tissue formation. Clinically, these conditions appear as "gingival overgrowth" (GO), which can be of drug-induced or genetic origin. Despite surgical removal, GO can recur. Therefore, non-invasive methods of treating GO are required. In other fibrotic systems, the matricellular protein CCN2 represents a potential therapeutic target. However, CCN2 has been relatively understudied in the context of GO.
Highlight: Herein, we describe what is known regarding CCN2 expression in GO and gingival fibroblasts. Specifically, CCN2 is induced by agents that promote fibrogenesis in the oral cavity, such as transforming growth factor-β, and drugs that promote GO, such as cyclosporine, nifedipine, and phenytoin.
Conclusion: Although little is known regarding the possible function of CCN2 in GO, given the correlation between CCN2 expression and GO recurrence, we hope that this review will inspire further research on this topic.